PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
L. H. Schmidt(University Hospital Münster), Wolfgang Hartmann(University Hospital Münster)
Cited by 228
Related Papers
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
|Nature Medicine|2016|185
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
|Nature Communications|2019|72
Phosphatidylinositol‐3′‐kinase/AKT signaling is essential in synovial sarcoma
|International Journal of Cancer|2010|52
<scp>SRC</scp> inhibition represents a potential therapeutic strategy in liposarcoma
|International Journal of Cancer|2015|24
SS18-SSX drives CREB activation in synovial sarcoma
|Cellular Oncology|2022|9